Drug Trial Radar · NCT05902988
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 18, 2023
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Volastra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Conditions
- Advanced Solid Tumor
- High Grade Serous Adenocarcinoma of Ovary
- Squamous Non-small-cell Lung Cancer
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Ovarian Carcinosarcoma
- Uterine Carcinosarcoma
- Uterine Serous Carcinoma
- Endometrium Cancer
- Chromosomal Instability
Interventions
VLS-1488Drug
VLS-1488 tablets will be given orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjectsTime frame: Up to 12 months
- Dose Escalation: Determination of the MTD of VLS-1488Time frame: Up to 12 months
- Dose Escalation: Frequency of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0Time frame: Up to 12 months
- Dose Escalation: Frequency of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0Time frame: Up to 12 months
- Dose Escalation: Frequency of Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0Time frame: Up to 12 months
- Dose Escalation: Frequency of Dose Interruptions and Permanent Treatment DiscontinuationsTime frame: Up to 12 months
- Dose Expansion: Frequency of Trigger Events (TEs)Time frame: Up to 18 months
- Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Up to 18 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California · Recruiting
Hoag Memorial Hospital
Newport Beach, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Kellogg Cancer Center
Evanston, Illinois · Recruiting
Community Health Network
Indianapolis, Indiana · Recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
START Midwest
Grand Rapids, Michigan · Active not recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The Christ Hospital
Cincinnati, Ohio · Recruiting
Women & Infants Hospital
Providence, Rhode Island · Recruiting
M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.